VAC-02 - Réponse vaccinale après greffe allogénique de cellules souches hépatopoïétiques : étude de cohorte prospective
Florent Valour(Université Claude Bernard Lyon 1), Florence Ader(Université Claude Bernard Lyon 1), Carole Wehbe Chidiac(Hospices Civils de Lyon), Fiorenza Barraco(Hôpital Lyon Sud), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Mauricette Michallet(Institut d’Hématologie et d’Oncologie Pédiatrique), Anne Conrad(Lyon 1 Université), Marie Balsat(Hôpital Claude Huriez), X. Thomas(Hôpital Edouard Herriot), C. Roure-Sobas(Hôpital de la Croix-Rousse)
Cited by 0
Related Papers
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
|The Lancet|2022|407
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309